Bora Pharmaceuticals Adds Roller Compaction Capabilities

Bora Pharmaceutical Laboratories, a division of Bora Pharmaceuticals, has added roller compaction technology to its solid dose capability offerings at its Zhunan, Taiwan contract manufacturing and packaging facility. The Zhunan facility is a leader in the manufacture of complex oral solid dose (OSD) formulations with expertise in the use of solvents, Wurster Coating, or Extrusion-Spheronization.

UST Named Market Leader in ISG Provider Lens™ Healthcare Digital Services Report

Qlucore secures SEK 30 million (USD 3.5m) for international expansion

The Swedish AI software company Qlucore AB (“Qlucore” or “the Company”) – with more than 200 international customers – today announces that it has secured SEK 30 million before transaction costs in a pre-IPO private placement. The raised capital will predominantly be used to accelerate sales activities and expand the technical team prior to an initial public offering (IPO), planned within the next twelve months.

Court Square Group and 5thPort Announce Life Science Industry Partnership

Court Square Group and 5thPorts Partnership helps life science companies streamline clinical trials and improve outcomes

Arkema chooses Dotmatics as R&D digitalization partner

Comparably Recognizes IntelyCare as a Best Place to Work in Boston

BOC Sciences Provides Extensive Catalog of Isotope Labeled Products

Genomenon and Limbus Partner to Advance Genomic Variant Interpretation

Genomenon® announced a partnership with Limbus Medical Technologies, which includes integration of the Mastermind® Genomic Search Engine into the cloud-based varvis® platform. In the initial integration available now, users of varvis can preview the number of published articles related to their search and easily link out to view the evidence in Mastermind. A deeper integration using Mastermind’s advanced API is underway, which will allow users to view the relevant evidence right inside the varvis platform.

CD BioSciences Introduces First-in-Human (FIH) Study Service

CD BioSciences, a professional US provider of integrated solutions for clinical trials development, has introduced first-in-human (FIH) study service to biological and pharmaceutical institutes and companies for drug development needs.

Kyruus Joins athenahealth’s Marketplace Program to Enable Joint Customers to Offer Seamless Online Appointment Scheduling

BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes

LabVantage Launches Full-Featured Self-Service Advanced Analytics Solution

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the launch of LabVantage Analytics, a full-featured, self-service advanced analytics solution that lets users easily explore, analyze, and visualize LIMS, enterprise, and external data to gain actionable business insights. Designed by analytics industry experts, LabVantage Analytics seamlessly integrates with all elements of the LabVantage LIMS platform, providing a single user interface and workflow.

LabVantage Solutions Names Digital Transformation Leader Mikael Hagstroem as CEO

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, has appointed Mikael Hagstroem as Chief Executive Officer.

LabVantage Emphasizes Cybersecurity with Version 8.6 of Its LIMS Platform

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced that the 8.6 edition of its flagship LIMS has been designed and tested to optimum cybersecurity standards.

LabVantage Adds Vendor Validation to Its Software-as-a-Service LIMS

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced it has added validation to a number of its subscription-based LIMS. Adding validation support to a cloud-hosted, Software-as-a-Service (SaaS) LIMS increases confidence for organizations that function in regulated sectors, such as pharmaceuticals, biobanking, and clinical and molecular diagnostics.

New Healthcare Industry Survey Reveals Majority of Healthcare Organizations Unprepared for ONC Cures Act Final Rule

MedAI Integrates Its Drug Research and Development Platform for the Pharmaceutical Industry

Earlier this month, MedAI announces to have integrated its drug research and development platform for the pharmaceutical industry. The company is specialized in AI-assisted R&D and it now provides a wide range of solutions that covers nearly every stage of early drug development, including developing drug targets, biomarker discovery, chemical drug development, protein/antibody development, prediction of drug, crystal form, ADMET prediction, repurposing existing drugs, drug formulation development.

Kiniciti Welcomes Two Cell and Gene Therapy Industry Leaders to its Advisory Board

Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in non-therapeutic companies supporting Cell and Gene Therapy innovation, announced the formation of an Advisory Board and appointment of two inaugural members: Denis Bedoret, PhD, chief executive officer of Imcyse, and Andrew Knudten, chief operating officer of Jaguar Gene Therapy.

Cresset expands its Board with the appointment of David Newble as Non-Executive Director

Seven Bridges Launches the GRAF™ Population Solution — Population-Specific Tools and Services to Enhance Genetic Variation Discovery

Bioinformatics methods suffer from a significant loss of accuracy when used on sequencing data from under-represented populations because the genetic information of such populations cannot be captured in the linear reference genome. The inherent bias in the industry’s current reference genome favors the European population. A pan-genome approach can provide significant improvements, but it is still suboptimal. The Seven Bridges GRAF Population Solution is ancestry-aware and, therefore, more accurate than both linear and pan-genome approaches.